| Dr Nick Maravich, MD | |
|
210 Ark Rd, Mount Laurel, NJ 08054-3188 | |
| (856) 778-8860 | |
| (609) 261-4180 |
| Full Name | Dr Nick Maravich |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 30 Years |
| Location | 210 Ark Rd, Mount Laurel, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104828599 | NPI | - | NPPES |
| 7542607 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 25MA06540900 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua Memorial Hospital Of Burlington County | Mount holly, NJ | Hospital |
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Willingboro Hospital | Willingboro, NJ | Hospital |
| Atlanticare Regional Medical Center | Atlantic city, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Larchmont Imaging Associates Llc | 5193762433 | 23 |
| Radiology Associates Of Burlington County, P.a. | 7012954381 | 56 |
| South Jersey Radiology Associates, P.a. | 9133115587 | 60 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.
Summer has barely begun but it's likely many people have already encountered one of the season's most ubiquitous pests - the mosquito. As is the case with many other insects, mosquitoes have made an early emergence after a mild winter and rainy spring. The National Pest Management Association (NPMA) warns that this might be one of the worst seasons yet, so break out the repellant.
The American Association of Critical-Care Nurses (AACN) expands its hospital-based nurse leadership and innovation training program to a fourth region with the addition of eight Austin-area hospitals.
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.
› Verified 7 days ago
| Entity Name | South Jersey Radiology Associates, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477551653 PECOS PAC ID: 9133115587 Enrollment ID: O20040422000102 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.
Summer has barely begun but it's likely many people have already encountered one of the season's most ubiquitous pests - the mosquito. As is the case with many other insects, mosquitoes have made an early emergence after a mild winter and rainy spring. The National Pest Management Association (NPMA) warns that this might be one of the worst seasons yet, so break out the repellant.
The American Association of Critical-Care Nurses (AACN) expands its hospital-based nurse leadership and innovation training program to a fourth region with the addition of eight Austin-area hospitals.
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.
› Verified 7 days ago
| Entity Name | Larchmont Imaging Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710932603 PECOS PAC ID: 5193762433 Enrollment ID: O20050408000523 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.
Summer has barely begun but it's likely many people have already encountered one of the season's most ubiquitous pests - the mosquito. As is the case with many other insects, mosquitoes have made an early emergence after a mild winter and rainy spring. The National Pest Management Association (NPMA) warns that this might be one of the worst seasons yet, so break out the repellant.
The American Association of Critical-Care Nurses (AACN) expands its hospital-based nurse leadership and innovation training program to a fourth region with the addition of eight Austin-area hospitals.
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.
› Verified 7 days ago
| Entity Name | Radiology Associates Of Burlington County, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255385183 PECOS PAC ID: 7012954381 Enrollment ID: O20050408000763 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.
Summer has barely begun but it's likely many people have already encountered one of the season's most ubiquitous pests - the mosquito. As is the case with many other insects, mosquitoes have made an early emergence after a mild winter and rainy spring. The National Pest Management Association (NPMA) warns that this might be one of the worst seasons yet, so break out the repellant.
The American Association of Critical-Care Nurses (AACN) expands its hospital-based nurse leadership and innovation training program to a fourth region with the addition of eight Austin-area hospitals.
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nick Maravich, MD 1295 Route 38, P.o. Box 479, Hainesport, NJ 08036-2702 Ph: (609) 261-7017 | Dr Nick Maravich, MD 210 Ark Rd, Mount Laurel, NJ 08054-3188 Ph: (856) 778-8860 |
News Archive
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. The investigational medicine met statistical significance for all primary endpoints except for one measurement at Month 3 in one of the trials. These late-breaking data were presented here today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.
Most doctors treat Lyme disease with antibiotics for two to four weeks after diagnosis, but if symptoms persist after that, medical guidelines recommend against antibiotic retreatment. That recommendation may not be warranted. A newly published statistical review of the four studies upon which those guidelines are based reports flaws in design, analysis, and interpretation that call into question the strength of the evidence against retreatment.
Summer has barely begun but it's likely many people have already encountered one of the season's most ubiquitous pests - the mosquito. As is the case with many other insects, mosquitoes have made an early emergence after a mild winter and rainy spring. The National Pest Management Association (NPMA) warns that this might be one of the worst seasons yet, so break out the repellant.
The American Association of Critical-Care Nurses (AACN) expands its hospital-based nurse leadership and innovation training program to a fourth region with the addition of eight Austin-area hospitals.
Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.
› Verified 7 days ago
Dr. Howard S. Berinson, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 210 Ark Rd, Mount Laurel, NJ 08054 Phone: 856-261-4500 Fax: 609-261-4180 | |
Dr. Robert T. Harvey, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 Ark Rd, Mount Laurel, NJ 08054 Phone: 856-778-8860 Fax: 609-261-4180 | |
Dr. Britton Miller Chan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 Ark Road, Mount Laurel, NJ 08054 Phone: 609-914-7017 | |
Dr. Sungtae Lim, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 Ark Rd, Mount Laurel, NJ 08054 Phone: 856-778-8860 Fax: 609-261-4180 | |
Dr. Priyesh Patel, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 210 Ark Rd, Mount Laurel, NJ 08054 Phone: 609-261-4500 Fax: 609-261-4180 | |
Dr. Kevin P. Barry, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 210 Ark Rd, Mount Laurel, NJ 08054 Phone: 856-778-8860 Fax: 609-261-4180 |